Vivani Medical, Inc. (VANI)
NASDAQ: VANI · Real-Time Price · USD
1.230
0.00 (0.00%)
At close: Dec 31, 2025, 4:00 PM EST
1.250
+0.020 (1.63%)
After-hours: Dec 31, 2025, 5:16 PM EST
Vivani Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
89.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 3.38M | -3.52M | -51.00% |
| Dec 31, 2018 | 6.90M | -1.07M | -13.41% |
| Dec 31, 2017 | 7.96M | 3.98M | 99.85% |
| Dec 31, 2016 | 3.99M | -4.97M | -55.47% |
| Dec 31, 2015 | 8.95M | 5.55M | 163.39% |
| Dec 31, 2014 | 3.40M | 1.83M | 117.12% |
| Dec 31, 2013 | 1.57M | 197.78K | 14.47% |
| Dec 31, 2012 | 1.37M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VANI News
- 6 weeks ago - Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Vivani Medical, Inc. Announces Closing of Common Stock Offering - GlobeNewsWire
- 2 months ago - Vivani Medical, Inc. Announces Pricing of Common Stock Offering - GlobeNewsWire
- 3 months ago - Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off - GlobeNewsWire
- 3 months ago - Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025 - GlobeNewsWire
- 3 months ago - Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders - GlobeNewsWire
- 4 months ago - Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management - GlobeNewsWire
- 4 months ago - Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 - GlobeNewsWire